RxSight Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Arrangements
On November 20, 2024, Ron Kurtz M.D., our President and Chief Executive Officer and a member of our Board of Directors, terminated his Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) dated September 1, 2023.
On December 6, 2024, Ron Kurtz M.D., our President and Chief Executive Officer and a member of our Board of Directors, entered into a Rule 10b5-1 Trading Plan for the sale of shares of our common stock. Dr. Kurtz's Rule 10b5-1 Trading Plan, which has a term from December 6, 2024 to March 6, 2026, provides for the sale of up to 448,635 shares of common stock.
On December 11, 2024, Dr. Tamara Fountain, amember of our Board of Directors, entered into a Rule 10b5-1 Trading Plan for the sale of shares of our common stock. Dr. Fountain's Rule 10b5-1 Trading Plan, which has a term from December 11, 2024 to December 11, 2025, provides for the sale of up to 7,000 shares of common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.